09192017Headline:

CureVac to Present at Upcoming International Investor Conferences

May 18, 2017 - (Newswire)

- CureVac AG, the most clinically advanced mRNA company, today announced that the company will present at two upcoming international investor conferences: UBS 2017 Global Healthcare Conference in New York, NY; and Bio€quity Europe in Paris, France.

Executives from CureVac will provide an overview of the company's business, industry-leading mRNA technology platform, and clinical-stage product pipeline during each presentation and will be available to participate in one-on-one meetings with investors who are registered to attend each conference.

Event:


UBS 2017 Global Healthcare Conference

Presenter:


Pierre Kermula, Chief Financial Officer

Date:


Monday, May 22, 2017

Time:


2:30 - 3:00 pm, ET

Location:


Grand Hyatt, New York, NY - Ballroom IV

Event:


Bio€quity Europe

Presenter:


Dr. Franz-Werner Haas, Chief Corporate Officer

Date:


Monday, May 22, 2017

Time:


3:40 - 4:00 pm, CET

Location:


Marriott Rive Gauche, Paris, France- Forum EF, Level -1

About CureVac AG

Founded in 2000 as a spin-off from the University of Tϋbingen in Germany, CureVac is a technology leader in the development of drugs that are based on the molecule Messenger RNA (mRNA). The fully integrated biopharmaceutical company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes.

The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies.

Since its inception, strongly backed by SAP founder Dietmar Hopp's dievini CureVac has received approximately $370 million (€355 million) in equity investments including an investment of the Bill & Melinda Gates Foundation of $ 52million in 2015. CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, the Bill & Melinda Gates Foundation and IAVI.

In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2016 CureVac started the establishment and construction of industrial scale production facilities.

For more information, please visit www.curevac.com

Media Contacts
Verena Lauterbach, Senior Manager Communications
CureVac AG, Tübingen, Germany
T: +49 (0) 7071 9883 1756
verena.lauterbach@curevac.com

Andrew Mielach, Vice President
Tiberend Strategic Advisors, New York
T: +1 212 375 2694
amielach@tiberend.com

SOURCE CureVac AG

Original Source: https://www.newswire.com/news/curevac-to-present-at-upcoming-international-investor-conferences

What Next?

Related Articles

Leave a Reply

Submit Comment